相关临床试验
1
0 进行中
药物批准
90
批准总数
监管机构
1
监管机构数
成立时间
N/A
已完成
1
100.0%
- ABION's ABN202, based on the proprietary iRAC platform, demonstrated superior anti-cancer mechanisms compared to currently approved TROP2-targeting ADCs in preclinical studies. - The drug candidate overcame resistance to TROP2-targeting ADCs and showed superior anti-tumor efficacy compared to ADCs combined with anti-PD-1 immune checkpoint inhibitors. - ABN202 induced sustained and systemic CD8-positive T cell-mediated immune responses, suggesting potential for durable anti-tumor immunity in solid tumor patients. - The company is accelerating preclinical development toward IND submission in the first half of next year while exploring strategic partnership opportunities.
The FDA has approved modifications to the Phase 2 clinical trial for vabametkib, Abion's c-MET targeted anticancer drug, in combination with lazertinib for non-small cell lung cancer patients. The trial will evaluate this novel combination therapy in patients who have developed resistance to EGFR-targeted treatments, addressing a significant unmet need in NSCLC treatment.
